方法：前瞻性随机对照临床试验研究，选择新生血管性青光眼34眼，排除前房浅的患者，随机分为两组。第一组(A组)15眼行Ex-PRESS青光眼引流器植入术，术中应用丝裂霉素； 第二组(B组)19眼行小梁切除术，术中应用丝裂霉素。随访1a，观察两种手术前后眼内压，视力变化，以及随访期间联合应用降眼压药物情况，并发症情况，结果进行统计学分析。

结果：两组治疗前后的平均眼压均有明显的下降(P=0.01)。两组在治疗后1，4wk； 6，12mo的眼压变化相似，没有明显差异(P=0.451)。两组1，4wk； 6，12mo的最佳矫正视力与治疗前相比没有明显变化(P=0.832)。Ex-PRESS青光眼引流器植入术组和小梁切除组成功率分别是66.7%和63.1%。小梁切除组8例患者出现了前房出血，Ex-PRESS青光眼引流器植入术组有3例患者发生了前房出血。术后早期小梁切除组6例患者发生了脉络膜脱离，Ex-PRESS青光眼引流器植入术组有3例患者出现了脉络膜脱离。

结论：Ex-PRESS青光眼引流器植入术治疗新生血管性青光眼相对简便、安全、微创、学习曲线短，患者痛苦小，并发症少，是治疗新生血管性青光眼的一种有效方法。

METHODS: This prospective study comprised 34 eyes of 34 patients who suffered from NVG, excluding patients with shallow anterior chamber. All patients were assigned to groups A and B according the different therapy. Group A(15 eyes)was treated with Ex-PRESS glaucoma filtration device implantation. Group B(19 eyes)underwent a trabeculectomy combined with mitomycin C. All the patients were followed up to 1a. The results of best-corrected visual acuity(BCVA), intraocular pressure(IOP), the combination of IOP lowering medications, complications were recorded statistically analyzed preoperative and 1d, 1, 4wk, 6 and 12mo after operation.

RESULTS: Mean IOP decreased significantly frompreoperative values in both groups(P=0.01). The both group had similar IOP values changes after 1, 4wk, 6, 12mo, and there were no significant difference in statistics(P=0.451). There was no significant difference in BCVA changes after operation in both groups(P=0.832). Success rate was 66.7% and 63.1% at 1a after Ex-PRESS glaucoma filtration device and trabeculectomy, respectively. Anterior chamber bleeding occurred to 8 cases after trabeculectomy in group B and to 3 cases with Ex-PRESS glaucoma filtration device implantation in group A. Choroidal detachment occurred to 3 cases in group A and 6 cases in group B. No other ocular or systemic adverse events were found during the follow-up duration.

CONCLUSION: In the short-term, Ex-PRESS glaucoma filtration device implantation has the advantages of simpleness, safety, minimally invasive, short learning curve for neovascular glaucoma, which provides us an available strategy to conquer NVG by simply operation and less suffering.